Biomarker

Stoke Therapeutics: Barry Ticho

"RNA modulation as a field has really come into its own."

Oct 27 • 

Dylan Neel, MD PhD

6

3

Seal the Deal: Neuroscience

Early-stage biotech M&A and partnerships: Part 1 (Neuro)

Oct 21 • 

Dylan Neel, MD PhD

, 

Aditya Raj

, and 

ArmaanBahl

13

3

June 2025

Mass General Brigham: Merit Cudkowicz

“We need to lower barriers for patient enrollment into trials in the US”

Jun 30 • 

Dylan Neel, MD PhD

4

Novartis: Robert Baloh

“I found that I was most passionate about making new therapies for patients”

Jun 10 • 

Dylan Neel, MD PhD

5

Trace Neuroscience: Eric Green

“Organizations that have a clear, shared purpose are powerful”

Jun 2 • 

Dylan Neel, MD PhD

5

September 2024

Superluminal: Ajay Yekkirala

Listen now |

Sep 23, 2024 • 

Dylan Neel, MD PhD

3

1:03:55

August 2024

Voyager: Al Sandrock

“All it takes is to meet one patient who has benefited from a drug you helped to develop.”

Aug 20, 2024 • 

Dylan Neel, MD PhD

4

July 2024

Novartis: Jennifer Brogdon

"There is no script or playbook for this scenario—but we felt that we were mapping a new landscape in medicine."

Jul 16, 2024 • 

Dylan Neel, MD PhD

6

June 2024

Lab Meeting: Maria Grazia Roncarolo

"Tr1 cells have the potential to not only provide symptom relief, but also reset the immune system to provide cures.”

Jun 18, 2024 • 

Dylan Neel, MD PhD

 and 

Tito Adhikary

3

April 2024

Radiopharm Renaissance

Case studies, market dynamics and technical hurdles for radioligand therapies

Apr 30, 2024 • 

Dylan Neel, MD PhD

, 

Joseph Mekhael

, and 

Dennis Gong

6

24 Biotech Investors in 2024

Rising stars in biotech investing and creation discuss how they got started, lessons learned and tips to break into the industry.

Apr 8, 2024 • 

Dylan Neel, MD PhD

 and 

Shreya Mantri

13

March 2024

Lab Meeting: Mike Rosenblatt

“The biggest breakthroughs are those that wipe away disease.”

Mar 11, 2024 • 

Dylan Neel, MD PhD

3